

BIG PHARMA MONOPOLY & IMPUNITY DURING COVID19 PANDEMIC

Rachmi Hertanti

Indonesia for Global Justice (IGJ)

Member of IOC AEPF


29 June 2021



Indonesia for Global Justice

Fig. 3: Cumulative vaccine doses administered per 100 people in the total population.

From: A global database of COVID-19 vaccinations




Shown are the global data as of 7 April 2021. Single doses are counted, and may not equal the total number of people vaccinated, depending on the specific dose regime (some people may have received multiple doses).

Vaccine Inequality

Source: A journal on A global database of COVID-19 vaccinations published by Nature Human Behaviour
<https://www.nature.com/articles/s41562-021-01122-8#Fig3>

Rich countries will get access to coronavirus vaccines earlier than others



<https://www.openglobalrights.org/secretary-brand-vaccines-and-non-cooperation-in-the-access-to-covid-in-latin-america/>

AGENDA VAKSINASI INDONESIA

**TARGET 426 JUTA
DOSIS VAKSIN**
(181 juta penduduk ditambah dengan
cadangan 15%)

"tantangan terbesar kita adalah bagaimana kita bisa segera mendatangkan suplai atau mendatangkan vaksin. Hal itu terjadi karena saat ini kondisi permintaan dengan ketersediaan vaksin Covid-19 di dunia tidak seimbang. Selain itu, hanya ada beberapa negara yang dapat memproduksi vaksin Covid-19"

Ganti Winarto – Kimia Farma

VAKSIN YANG DIPESAN

Sebanyak 329,5 juta dosis vaksin yang dipesan pemerintah kepada lima perusahaan :

- 125,5 Juta Vaksin SINOVAC
- 50 Juta Vaksin PFIZER
- 50 Juta Vaksin ASTRAZENECA
- 54 Juta Vaksin COVAC/GAVI
- 50 Juta Vaksin NOVAVAC

PASOKAN VAKSIN PER - JUNI 2021

Pemerintah Indonesia telah mengamankan **94.728.400 dosis vaksin** dengan rincian :

- SINOVAC (84.500.000 Dosis),
- ASTRAZENECA (8.228.400 Dosis)
- SINOPHARM (2.000.000 Dosis)



PER-JUNI 2021

Baru sekitar **32.603.744 orang** yang telah divaksinasi per Juni 2021 secara total dosis 1 dan dosis 2

Vaksin yang masih dibutuhkan untuk memenuhi target Herd Immunity sekitar 181,5 juta masyarakat Indonesia adalah :

**331.271.000
DOSIS VAKSIN**

The vaccines that **have been ordered by the Government of Indonesia bilaterally and multilaterally are 329.5 million doses of vaccine** to five companies, consisting of: 125.5 million doses of vaccine from Sinovac. Then, 50 million doses of vaccine were ordered from Novavax, 54 million doses of vaccine from Covax/GAVI, 50 million doses of vaccine from AstraZeneca, and 50 million doses of vaccine from Pfizer.

As of June 2021: The Indonesian government has secured 94,728,400 doses of vaccine: **Sinovac (84,500,000 doses), AstraZeneca (8,228,400 doses) and Sinopharm (2,000,000 doses)**

Vaccines that are still needed to meet the Herd Immunity target of around 181.5 million Indonesians are: **331,271,000 doses of vaccine.**

IP MONOPOLY ON HEALTH PRODUCTS

Health Product(s)	Type(s) of IPR
Test kits, diagnostics	Patent rights, trade secrets
Masks (esp. N95 respirator)	Patent rights, industrial designs
Medicines	Patent rights
Vaccines	Patent rights, trade secrets
Ventilators Ventilators – ventilator valves, programs, machines, software, etc.	Patent, trade, secrets, industrial designs, copyrights, and others https://www.medicaldevice-network.com/news/3d-printed-valves-covid-19-italy/
Artificial intelligent	

Source: TWN

Defending the protection of the IPR monopoly also goes against the COVID-19 medicines and vaccines to be treated as global public goods.

PROFITEERING BEHAVIOR

Brook Baker (March 2021) – Pfizer and BioNTech Profiteering Exposed:

*...we can realistically hazard a guesstimate that **total R&D expenditures on the vaccine were \$1 billion or less.** And don't forget, **BioNTech got \$445 million from Germany** to speed up its vaccine development and for initial investments in expanded manufacturing capacity.*


Compare these R&D expenditures with projected earnings.

*Pfizer is already on record **predicting \$15 billion in earnings** from the vaccine this year. **BioNTech's estimate is \$11.5 billion.** But these projections are based on 1.4 billion doses only. The partnership is planning to increase production up to 2.5 billion doses by end of the year. Selling those additional .9 billion doses at \$19.50, the U.S. price, would yield another \$17.55 billion in revenue (note: Pfizer had already predicted another possible \$15 billion in sales).*

BILATERAL DEALS & LICENSING

Vaccine makers are charging different prices

Price per dose (\$USD)




WHERE VACCINES WILL BE PRODUCED

Most of the vaccines will be manufactured in the United States and Europe.

Vaccine manufacturer

■ Oxford/AstraZeneca
 ■ Sanofi/GSK
 ■ Novavax
 ■ Pfizer
■ Johnson & Johnson/Janssen
 ■ Curevac
 ■ Vaxart
 ■ Other



readersupportednews.org/news-section2/318-66/69029-held-to-ransom-pfizer-demands-governments-gamble-with-state-assets



A health care worker administers a dose of the Pfizer-BioNTech Covid-19 vaccine. photo: Roger Kirby/Bloomberg/Getty Images

'Held to Ransom': Pfizer Demands Governments Gamble with State Assets to Secure Vaccine Deal

By Madlen Davies, Rosa Furneaux, Ivan Ruiz and Jill Langdon, The Bureau of Investigative Journalism
24 April 21

Pfizer has been accused of "bullying" Latin American governments in Covid vaccine negotiations and has asked some countries to put up sovereign assets, such as embassy buildings and military bases, as a guarantee against the cost of any future legal cases, the Bureau of Investigative Journalism can reveal.

In the case of one country, demands made by the pharmaceutical giant led to a three-month delay in a vaccine deal being agreed. For Argentina and Brazil, no national deals were agreed at all. Any hold-up in countries receiving vaccines means more people contracting Covid-19 and potentially dying.

mg.co.za/coronavirus-essentials/2021-04-19-pfizer-backs-down-over-unreasonable-terms-in-south-africa-vaccine-deal/

COVID-19 IN SA NEWS OPINION ARTS & CULTURE BUSINESS EDUCATION HEALTH WEBINARS PARTNER FEATURE

CORONAVIRUS

Pfizer backs down over 'unreasonable' terms in South Africa vaccine deal

Madlen Davies Rosa Furneaux 19 Apr 2021



Note: all prices are subject to trade agreements

Source: Unicef, US Government contracts, WHO




©nature



Indonesia for Global Justice

OUR DEMANDS

- NO IP Monopoly
- We need alternative
- How can we ask Big Pharmaceutical Companies accountability that has prevented the states, especially in developing and underdeveloped countries, to implement their obligations fulfilling the right to health in their countries?



THANK YOU



- <https://www.openglobalrights.org/secretcy-brand-vaccines-and-non-cooperation-in-the-access-to-covid-in-latin-america/>
- <https://www.msf.org.za/news-and-resources/publications/covid-19-vaccines-how-big-pharma-s-secrets-and-protected-monopolies>
- <https://healthgap.org/pfizer-and-biontech-profiteering-exposed-more-than-enough-is-enough/>
- <https://www.dw.com/en/india-south-africa-bid-to-ban-covid-vaccine-patents-finds-few-takers-in-latin-america/a-58048258>
- <https://msfaccess.org/astrazeneca-must-open-books-prove-no-profit-pricing-commitment-and-make-all-licenses-and-agreements>

